How Integrilin (Eptifibatide) is Given and Why
Eptifibatide is administered as an intravenous double-bolus followed by continuous infusion during percutaneous coronary intervention (PCI) for acute coronary syndromes to prevent thrombotic complications and reduce death or myocardial infarction.
Administration Protocol
Dosing Regimen
For patients undergoing PCI who have NOT received prior P2Y12 inhibitor therapy:
- Loading dose: 180 mcg/kg IV bolus, followed 10 minutes later by a second 180 mcg/kg IV bolus 1
- Maintenance infusion: 2.0 mcg/kg/min, started after the first bolus 1
- Duration: Continue infusion for 12-18 hours at physician discretion 1, 2
Renal dosing adjustment: Reduce infusion by 50% in patients with estimated creatinine clearance <50 mL/min 1
Clinical Context
The double-bolus regimen is specifically recommended to support PCI in both STEMI and UA/NSTEMI patients with normal renal function 1, 2. This dosing strategy emerged from the ESPRIT trial, which demonstrated that higher doses (180/2.0 mcg regimen) were significantly more effective than earlier lower-dose regimens 3.
Why It's Used
Primary Indication
Eptifibatide is a glycoprotein IIb/IIIa receptor inhibitor that blocks the final common pathway of platelet aggregation 4. It reduces the composite endpoint of death, myocardial infarction, and urgent revascularization by approximately 35-37% when used during PCI 3, 5.
Evidence-Based Benefits
The PURSUIT trial demonstrated that eptifibatide reduced 30-day death or MI from 15.7% to 14.2% (p=0.042) in UA/NSTEMI patients 6. The benefit was even more pronounced in patients undergoing early intervention, with event rates dropping from 16.7% to 11.6% (p=0.01) 3.
The ESPRIT trial showed a 37% reduction in the 48-hour composite endpoint (10.5% placebo vs 6.6% eptifibatide, p=0.0015) during coronary stent implantation 3, 5.
Treatment Strategy Algorithm
When to Use Eptifibatide
Class I recommendation (should be used):
- UA/NSTEMI patients undergoing PCI who have NOT received clopidogrel pretreatment 3
Class IIa recommendation (reasonable to use):
- UA/NSTEMI patients undergoing PCI who HAVE received clopidogrel 3
- STEMI patients undergoing primary PCI 7, 2
- Patients with large thrombus burden, no-reflow, or slow flow during PCI 8
Of uncertain benefit:
- Patients who received initial medical treatment with P2Y12 inhibitors 1
Timing Considerations
Do NOT use routine upstream (early) eptifibatide before angiography. The EARLY ACS trial definitively showed that routine administration 12+ hours before angiography was not superior to delayed provisional use at the time of PCI and increased bleeding risk (2.6% vs 1.8% TIMI major hemorrhage, p=0.02) 7, 2, 9.
Administer eptifibatide at the time of PCI rather than hours before cardiac catheterization 8, 9.
Important Caveats
Bleeding Risk
Major bleeding occurs more frequently with eptifibatide (1.3% vs 0.4% placebo in ESPRIT) 5. However, severe intracranial bleeding remains rare (0.2%) 4. The increased bleeding is predominantly associated with invasive procedures 6.
Thrombocytopenia
Significant thrombocytopenia (<20,000/μL) occurs in <1% of patients 4. Monitor platelet counts, particularly in high-risk populations 10.
Patient Selection
Avoid in:
- Patients with baseline negative troponin (no demonstrated benefit) 7, 2
- Patients >75 years old without positive troponin (increased bleeding without clear benefit) 7, 2
Prioritize in:
- Troponin-positive patients 7, 2
- Diabetic patients 7, 2
- High-risk patients judged to have thrombotic risk exceeding bleeding risk 2
Contemporary Context
With modern use of potent P2Y12 inhibitors (prasugrel, ticagrelor), the incremental benefit of routine glycoprotein IIb/IIIa inhibition has diminished 8. Reserve eptifibatide for bailout situations with procedural complications (thrombus, no-reflow) or high-risk anatomic features rather than routine use in all PCI cases 8.
Shorter Infusion Duration
Recent data suggest post-PCI eptifibatide infusions <18 hours (even <10 hours) may be feasible without worse ischemic outcomes in high-risk NSTE-ACS patients, potentially reducing bleeding complications 11.